Antisense Drug Trial Provides Key Insights About Huntington’s Disease
The halted GENERATION HD1 (GENHD1) study of the investigational antisense drug tominersen provided insights about Huntington’s disease staging and informed future clinical trials, researchers said. The phase III study involved 791 manifest Huntington’s disease patients who received intrathecal tominersen 120 mg either every 8 weeks or every 16 weeks, or placebo. Based on an overall […]